California State Teachers Retirement System Sells 5,324 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

California State Teachers Retirement System reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,385 shares of the company's stock after selling 5,324 shares during the period. California State Teachers Retirement System owned about 0.16% of IDEXX Laboratories worth $53,079,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after purchasing an additional 37,734 shares during the last quarter. Bamco Inc. NY increased its position in IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after buying an additional 82,264 shares during the last quarter. Invesco Ltd. raised its holdings in IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after buying an additional 74,324 shares in the last quarter. Norges Bank bought a new position in IDEXX Laboratories during the fourth quarter valued at about $412,258,000. Finally, Northern Trust Corp lifted its position in shares of IDEXX Laboratories by 18.6% in the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after buying an additional 143,369 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded down $3.03 during trading hours on Friday, reaching $512.52. 1,221,827 shares of the company's stock were exchanged, compared to its average volume of 652,599. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $530.60. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $41.22 billion, a P/E ratio of 48.03, a P/E/G ratio of 3.41 and a beta of 1.52. The business has a fifty day moving average price of $449.80 and a 200-day moving average price of $437.41.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the prior year, the company earned $2.71 EPS. The business's quarterly revenue was up 3.6% compared to the same quarter last year. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Stifel Nicolaus lifted their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research report on Monday, May 19th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director now directly owns 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.